Medicaid should go back to the drawing board on a key part of its proposal aimed at circumventing best price reporting obstacles to value-based purchasing.
The Centers for Medicare and Medicaid Services should flesh out and reintroduce its proposal to allow manufacturers to report multiple “best prices” in Medicaid before moving ahead with it as a means of facilitating value-based purchasing, biopharma manufacturers urged in recent comments to the agency.
Released in mid-June, the proposal is meant to remove some of the obstacles to value-based purchasing in the commercial market...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.
Vertex’s fertility preservation assistance program would provide up to $70,000 in financial support for in vitro fertilization and other services to patients prescribed Casgevy.
The agency says it will collect additional information from manufacturers on methods for adding up price concessions from the supply chain before moving ahead.
Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.
Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.
But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.
